YOU ARE HERE: LAT HomeCollectionsHepatitis B

Hepatitis B

December 10, 1998 | From Times Wire Reports
Sufferers of liver-destroying hepatitis B gained their first oral treatment: a drug that in higher doses is used to fight the AIDS virus. The Food and Drug Administration approved a lower dose of Glaxo Wellcome Inc.'s 3TC, or lamivudine, as a way to protect against the liver damage caused by chronic hepatitis B.
November 23, 1998 | SHARI ROAN
Parents of sixth-graders, if you think your child's immunization days are behind you, think again. A new state law requires all students entering seventh grade in the 1999 school year to be fully immunized for the hepatitis B virus by July 1. The hepatitis B immunization is a series of three shots spread out over seven or more months, so your child should get the first shot within the next month or two in order to be in compliance by July 1.
What a great sport boxing could be if it weren't for those darn blood tests. Tonight's title fight between heavyweight champion Evander Holyfield and challenger Henry Akinwande at Madison Square Garden was postponed Friday when results of medical tests taken Tuesday showed that Akinwande is in the acute stage of hepatitis B, an infectious but treatable disease. The possibility of this fight being rescheduled will depend on how advanced the disease is. Dr.
April 13, 1998
There are more than 25 diseases that are transmitted sexually. Many have serious and costly consequences. Some of the most common and serious STDs include: Chlamydia * Used to Be Called: Non-gonoccocal urethritis. * Cause: Bacteria. * Number Affected: About 4 million new cases each year in the United States. * Infection Rate: Highest among 15- to 19-year-olds, followed by 20- to 24-year-olds. * At Risk: Everyone, but female teens are more likely to be infected because of immature cervix.
April 7, 1998 | From Reuters
Shares of Gilead Sciences Inc. shot up nearly 20% Monday after the company released encouraging data about its drug to treat hepatitis B. Gilead jumped $7.13 to close at $43.25 on Nasdaq. The Foster City, Calif.-based company also released strong data from clinical trials of Preveon, a related drug for treating HIV-infected patients.
October 30, 1997 | From Times Staff and Wire Reports
Hundreds of residents who received flu shots at clinics in Monroe, Conn., are worried that they might have been exposed to viruses that cause hepatitis and AIDS, health officials said. They said many residents lined up for recommended hepatitis B shots after the scare. The shots are being given as a precaution because the town's health director, who has since resigned, did not change the syringe between flu shots that he gave to about 468 people.
June 26, 1997 | From Times staff and wire reports
The risk of liver cancer has fallen by half among children in Taiwan since hepatitis B vaccinations became routine a decade ago. Liver cancer is a major killer, especially in much of the developing world, and the hepatitis B virus is thought to be a major culprit. Taiwan began a program of vaccinating newborns against the virus in 1984--a program that has been adopted in the United States--and expanded it to schoolchildren in the late 1980s.
January 9, 1997 | From Times staff and wire reports
An experimental new vaccine is showing promise against malaria, which claims 2.7 million lives annually and has proved to be an exceptionally difficult target for vaccines. Scientists from SmithKline Beecham Biologicals have created a new vaccine that combines proteins from the parasite that causes malaria and from the hepatitis B virus. If it works, it will protect against both diseases. Dr. Jose A.
Beginning in July 1991, at least 19 people who underwent surgery at the UCLA Medical Center and a university-affiliated hospital contracted hepatitis B virus infection from a particular a surgeon, according to a federal investigation of the unusual outbreak released today. The study, published in the New England Journal of Medicine, does not say definitively how the unnamed surgery resident transmitted his hepatitis B infection to 13% of 144 patients he operated on over a year.
December 21, 1995 | From Times staff and wire reports
A medicine approved last month to treat AIDS also shows promise against hepatitis B. The drug, 3TC, suppresses the hepatitis B virus in people with chronic infections, stopping its damage to the liver, a team from Massachusetts General Hospital reported in the New England Journal of Medicine. About 1 million Americans are thought to be infected with hepatitis B, which, left untreated, can lead to cirrhosis, liver failure and liver cancer in a small portion of victims.
Los Angeles Times Articles